Commission incorporates Parliament views in revised FP7 proposal

The European Commission has adopted an amended proposal for the Seventh Framework Programme (FP7), which seeks to incorporate amendments made by the European Parliament and the Council of Ministers in their first readings. The Commission reports that the revised proposals "take up in spirit and content if not necessarily always with the exact wording, to a large proportion the position taken by the other institutions".

The Commission adopted its original FP7 proposal in April 2005, while the budgetary aspects to the programme were adopted in May 2006, following agreement on the EU's Financial Perspectives for 2007 to 2013. The Parliament adopted the proposals by a broad majority in June 2006, proposing some 1700 amendments.

The themes set to receive funding under the Cooperation programme remain the same, with a number of clarifications, specifying areas in which research will be funded. These range from healthy ageing and infectious diseases to soil fertility, the sustainability of fisheries, platforms for software and services and nano-composites.

On Joint Technology Initiatives (JTIs), long-term public-private partnerships to boost technology in specific fields, the Commission accepts modifications on the criteria to be used for identifying potential JTIs, as well as their organisation and implementation.

For example, the new proposal adds that when assessing the need for a JTI: the existence of a genuine societal need and benefit; the scale of the impact on industrial competitiveness and growth; and the inability of existing instruments to achieve the objective should all be taken into account.

The amended proposal also emphasises that small and medium sized enterprises (SMEs), technology transfer and education should not be neglected by JTIs. The organisation of JTIs should ensure that "participation in their projects is open to a wide range of participants throughout Europe, and in particular SMEs".

The Commission also incorporates important clarifications on the European Research Council (ERC), and in particular on the term of office, the renewal and the role of the Scientific Council, the management and staffing arrangements, and the independent review of the ERC.

MEPs had requested a review of the ERC in 2008. Speaking to the Parliament during a debate on FP7, EU Science and Research Commissioner Janez Potocnik suggested that this would be too soon. The revised proposal states that the review will be carried out 'no later than 2010'.

The new document adds that the ERC shall have the ability to conduct its own strategic studies to prepare and support its operational activities.

Ethics were a major consideration for many parliamentarians, and the revised proposal seeks to allay concerns by specifying which areas will not receive any funding under FP7. These are human cloning for reproductive purposes, research intended to modify the genetic heritage of human beings which could make such changes heritable, and research intended to create human embryos solely for the purpose of research or the purpose of stem cell procurement.

To follow the debate on FP7, please visit:

http://cordis.europa.eu/fp7/home.html

Copyright ©European Communities, 2006
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg – http://cordis.europa.eu.int. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Novartis and Microsoft Announce Collabor…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The...

Guerbet and IBM Watson Health Announce a…

Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, announced that it has signed a new agreement with IBM Watson Health to co-develop and...

Bayer Inks Deals with Eleven Startups un…

Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup companies aiming for longer-term collaborations...

Orion Health Delivers the First Health I…

The first Health Information Exchange (HIE) in the Middle East, Malaffi, went live at the end of July just six months after contracts were signed between the project company, Abu...

Joined Up Health and Care 2019 to Explor…

Professionals from across the country will come together to seek real answers on how to deliver closely integrated services, as the Joined Up Health and Care conference returns for its...

IMS MAXIMS Wins Healthcare Innovation Aw…

Health technology specialist IMS MAXIMS has been recognised for its innovative work in the UK and Irish healthcare market in the 2019 CV Business Innovator Awards. The company has been...

Health Tech Marketing and PR Agency Incr…

Highland Marketing, a full service agency for health techmarketing, PR and communications, has appointed Tia Dissanayake to a new account executive role,in which she will support the team withher life...

Brain-Computer Interfaces without the Me…

It sounds like science fiction: controlling electronic devices with brain waves. But researchers have developed a new type of electroencephalogram (EEG) electrode that can do just that, without the sticky...

Up-Close and Personal with Neuronal Netw…

How our brain cells, or neurons, use electrical signals to communicate and coordinate for higher brain function is one of the biggest questions in all of science. For decades, researchers...

Almirall Takes a Leap into Dermatology D…

Almirall, S.A. (ALM) has launched its first call for innovation to start-ups focused on dermatology digital health. This initiative is the first step in the creation of an accelerator programme...